Durect CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
DRRX
Durect CORPDURECT Corporation reported reduced losses in Q2 2025, with a pending acquisition by Bausch Health offering $1.75 per share plus contingent value rights.
DRRX
Durect CORPDURECT Corporation's Q1 2025 results show a reduced net loss compared to Q1 2024, but the company expresses substantial doubt about its ability to continue as a going concern.
DRRX
Durect CORPDURECT Corporation's Q3 2024 report reveals a net loss of $4.3 million, with ongoing efforts focused on the development of larsucosterol for alcohol-associated hepatitis and a strategic shift following the termination of the Innocoll agreement.
DRRX
Durect CORP10-Q: DURECT Corporation Reports Second Quarter 2024 Financial Results Amidst Going Concern Uncertainty
DURECT Corporation's Q2 2024 results show a net loss of $3.7 million and highlight concerns about the company's ability to continue as a going concern due to insufficient cash resources.
DRRX
Durect CORP10-Q: DURECT Corporation Reports First Quarter 2024 Financial Results Amidst Going Concern Uncertainty
DURECT Corporation's first quarter 2024 results show a net loss of $7.6 million and highlight concerns about the company's ability to continue as a going concern.